ProPhase Labs, Inc. Cash Equivalents, at Carrying Value
ProPhase Labs, Inc. (PRPH) had Cash Equivalents, at Carrying Value of $17.40 million as of 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashEquivalentsAtCarryingValue · last filed 2023-03-29
- 2022-12-31: Cash Equivalents, at Carrying Value $17.40M.
- 2022-09-30: Cash Equivalents, at Carrying Value $26.50M.
- 2022-06-30: Cash Equivalents, at Carrying Value $27.50M.
- 2022-03-31: Cash Equivalents, at Carrying Value $29.40M.
| Period end | Cash Equivalents, at Carrying Value |
|---|---|
| 2022-12-31 | $17.40M 10-K · filed 2023-03-29 |
| 2022-09-30 | $26.50M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $27.50M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $29.40M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $17.40M 10-K · filed 2022-03-31 |
| 2021-09-30 | $22.90M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |